Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY26 results · Jul–Sep 2025
Marksans Pharma reported revenue from operations of ₹720.41 crore (up 12.2% from Q2 FY25) and net profit of ₹99.14 crore (up 1.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 720.41 | 641.92 | +12.2% | 619.99 | +16.2% |
| Other income | 21.57 | 11.06 | +95.1% | 5.64 | +282.4% |
| Total income | 741.98 | 652.98 | +13.6% | 625.63 | +18.6% |
| Profit before tax | 133.33 | 124.60 | +7.0% | 76.60 | +74.1% |
| Net profit for the period | 99.14 | 97.76 | +1.4% | 58.20 | +70.3% |
| Attributable to shareholders of the company | 98.25 | 96.72 | +1.6% | 58.32 | +68.5% |
| EPS, basic (₹) | 2.17 | 2.13 | +1.9% | 1.29 | +68.2% |
| Net margin (%) | 13.8 | 15.2 | 9.4 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 320.44 | 308.62 | +3.8% | 319.73 | +0.2% |
| Other income | 58.19 | 31.36 | +85.6% | 2.01 | 29x |
| Total income | 378.63 | 339.98 | +11.4% | 321.74 | +17.7% |
| Profit before tax | 121.49 | 76.34 | +59.2% | 63.57 | +91.1% |
| Net profit for the period | 99.81 | 63.20 | +57.9% | 48.06 | +107.7% |
| EPS, basic (₹) | 2.20 | 1.39 | +58.3% | 1.06 | +107.5% |
| Net margin (%) | 31.1 | 20.5 | 15.0 |
Consolidated
- Filed with BSE
- 13 Nov 2025, 20:24 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2025, 20:24 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE